Takayuki Ikezoe

Fukushima, JP

Expertise in

conditions

Fukushima, JP

Overview

Takayuki Ikezoe practices practicing medicine in Fukushima, Japan.

Mr. Ikezoe is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Disseminated Intravascular Coagulation, Acid Sphingomyelinase Deficiency (ASMD), Leukemia, Paroxysmal Cold Hemoglobinuria, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 187 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Fukushima, Japan

Other Locations

Sapporo, Japan

Nankoku, Japan

Kochi, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)

Enrollment Status: Active_not_recruiting

Publish Date: July 01, 2026

Intervention Type: Drug

Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)

Study Phase: Phase 3

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Enrollment Status: Active_not_recruiting

Publish Date: June 12, 2026

Intervention Type: Drug

Study Drugs: Belantamab Mafodotin, Pomalidomide, Dexamethasone, Bortezomib

Study Phase: Phase 3

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Enrollment Status: Active_not_recruiting

Publish Date: November 26, 2025

Intervention Type: Drug

Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone

Study Phase: Phase 3

View 2 Less Clinical Trials

187 Total Publications

Coagulopathy in acute promyelocytic leukaemia: Can we better predict and prevent catastrophic bleeding?

Journal: Thrombosis research

Published: March 17, 2026

View All 187 Publications

Frequently Asked Questions about Takayuki Ikezoe

Is Takayuki Ikezoe a top-rated expert for Disseminated Intravascular Coagulation?

MediFind is an objective health platform that identifies experts based on real-world data. Takayuki Ikezoe is classified as an Elite expert for Disseminated Intravascular Coagulation, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Takayuki Ikezoe participate in research or clinical trials?

Yes. Takayuki Ikezoe has published 187 articles and abstracts on conditions like Disseminated Intravascular Coagulation. You can view a list of Takayuki Ikezoe's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ikezoe's expertise for a condition

ConditionClose